Dendritic cell-based approaches for therapeutic immune regulation in solid-organ transplantation by Vassalli, Giuseppe
Hindawi Publishing Corporation
Journal of Transplantation
Volume 2013, Article ID 761429, 17 pages
http://dx.doi.org/10.1155/2013/761429
Review Article
Dendritic Cell-Based Approaches for Therapeutic Immune
Regulation in Solid-Organ Transplantation
Giuseppe Vassalli1,2
1 Department of Cardiology, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
2Molecular Cardiology Laboratory, Fondazione Cardiocentro Ticino, 6900 Lugano, Switzerland
Correspondence should be addressed to Giuseppe Vassalli; giuseppe.vassalli@cardiocentro.org
Received 31 May 2013; Accepted 16 September 2013
Academic Editor: F. H. J. Claas
Copyright © 2013 Giuseppe Vassalli. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
To avoid immune rejection, allograft recipients require drug-based immunosuppression, which has significant toxicity. An
emerging approach is adoptive transfer of immunoregulatory cells.Whilemature dendritic cells (DCs) present donor antigen to the
immune system, triggering rejection, regulatory DCs interact with regulatory T cells to promote immune tolerance. Intravenous
injection of immature DCs of either donor or host origin at the time of transplantation have prolonged allograft survival in
solid-organ transplant models. DCs can be treated with pharmacological agents before injection, which may attenuate their
maturation in vivo. Recent data suggest that injected immunosuppressive DCs may inhibit allograft rejection, not by themselves,
but through conventional DCs of the host. Genetically engineered DCs have also been tested. Two clinical trials in type-1 diabetes
and rheumatoid arthritis have been carried out, and other trials, including one trial in kidney transplantation, are in progress or
are imminent.
1. Introduction
Allogeneic cell and solid-organ grafts trigger immune res-
ponses that cause destructive graft rejection in the absence
of sustained drug-based immunosuppression [1]. Unfor-
tunately, the latter is associated with major side effects
including severe infections and cancer, especially after many
years of treatment.Moreover, immunosuppressive drugs have
failed to prevent chronic graft rejection, which is primar-
ily manifested by allograft vasculopathy. The hope in the
immunotherapy field is to develop a therapy that targets
and neutralizes the alloimmune response selectively, while
leaving protective immunity intact.
Patients with a functioning allograft in the absence
of maintenance immunosuppression have been described
occasionally [2]. In some of them, immunosuppressive drugs
were discontinued because of infection or cancer [3]. Others
decided to stop taking the drugs [4]. Some liver transplant
recipients were enrolled in studies of weaning immunosup-
pression [5]. Moreover, some kidney transplant recipients
participated in studies of tolerance induction [6–9] which, in
part, included hematopoietic cell transplantation [8, 9].These
reports demonstrate the sporadic occurrence of operational
tolerance, as defined by lack of destructive graft rejection in
the absence of maintenance immunosuppression [10].
Sixty years ago, Billingham et al. described “actively
acquired tolerance” of foreign cells. They claimed that, “if
the first presentation of foreign cells takes place in fetal life,
resistance to a graft [from the same donor or from some
other member of the donor’s strain] transplanted on some
later occasion is abolished or at least reduced” [11]. This
concept implied the existence of regulatory mechanisms,
other than deletion of donor-reactive immune cells, favoring
graft acceptance. Thirty years later, Hall et al. reported that
rats that accepted cardiac allografts for extended periods of
time in the absence of treatment with cyclosporine or other
immunosuppressive drugs had suppressor T cells that actively
prevented graft rejection [12].
Multiple leukocyte populations including dendritic cells
(DCs), macrophages, T and B cells, and natural killer (NK)
cells participate in the immune reaction against the allograft
[1]. However, these populations include subsets of cells
showing regulatory activity. Analyses of immune cells in
patients who did not reject the allograft in the absence
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of drug-based immunosuppression revealed major roles for
regulatory T cells (Tregs) [13–15], regulatory B cells [16–
18], and regulatory DCs in the establishment of operational
tolerance. Regulatory immune cells are selected to either
exert inhibitory functions during development or acquire
regulatory activity within the graft or in draining lymphoid
tissue [2]. The balance between donor-reactive effector cells
and regulatory cells in the graft and its environment is
naturally shifted towards effector cells and graft rejection. In
this review, we wish to summarize our current understanding
of tolerogenic DCs favoring the development of antigen-
specific immune tolerance and graft acceptance (Table 1).
Emerging DC-based approaches for therapeutic immune
modulation in solid-organ transplantation, with a focus on
heart transplantation, are briefly discussed.
2. DC Populations
DC and monocyte lineages originate from a commonmono-
cyte and DC progenitor (MDP) that gives rise to monocytes
and committed DC progenitors (CDPs) in the bone marrow.
CDPs then give rise to pre-DCs that migrate to lymphoid
and nonlymphoid tissue and differentiate into the two major
populations of lymphoid tissue DCs and nonlymphoid tissue
CD103+ DCs [22, 23, 40]. Acting as antigen-presenting
cells, DCs trigger innate and adaptive immune responses
to microbial antigens and alloantigens, as well as to self-
antigens in autoimmune diseases. DCs initiate the innate
immune response through activation of NK cells. They also
set off the adaptive immune response through activation of
naive B and T lymphocytes. Besides their traditional role
as immunogenic cells, DCs regulate the immune reaction
andmediate peripheral T-cell unresponsiveness under home-
ostatic conditions in vivo [41]. The regulatory activity of
DCs can be accounted for by multiple mechanisms including
the production and release of anti-inflammatory cytokines
[32], Fas/Fas-ligand-induced apoptosis of effector immune
cells [42], deletion, and induction of Tregs [39, 43–46]
(Figure 1). Tolerogenic DCs comprise a majority of immature
DCs and subpopulations of DCs with various maturation
stages, including plasmacytoid DCs [43]. However, a major
drawback in vivo is the potential of tolerogenicDCs tomature
during infections or inflammation, which would convert
them into immunogenic cells [47].
DCs are a heterogeneous population. At least seven DC
subpopulations have been defined in mice based on differen-
tial expression of surface and intracellular markers [48–53].
The relationships between mouse and human DC popula-
tions are incompletely understood; however, recent compar-
ative genomics studies have revealed functional equivalences
between DC subsets in the two species [25]. Based on mor-
phology, cell-surface markers, and gene expression profiles,
DCs have traditionally been subdivided into classical and
plasmacytoid DCs [24, 27, 54–57]. The latter are character-
ized by the CD11clowCD45RAhiMHC-IIlow immunopheno-
type inmice and the CD4hiCD8negCD11clowCD45RAhiMHC-
IIlow immunophenotype in human [2].
Alternatively, a development-oriented nomenclature has
also been used [23]. This classification subdivides DCs into
conventional and monocyte-derived DCs . It is based on the
assumption that monocytes give rise tomucosal DCs, but not
to splenic, conventional DCs [58]. The existence of genuine
monocyte-derived DCs in vivo is presently being explored.
At steady state, most DCs in mouse lymphoid organs do not
arise from monocytes and depend upon fms-like transcript
3 ligand (Flt3L) for their development [59]. However, some
tissue (e.g., the gut) harbor macrophage colony-stimulating
factor (M-CSF)—dependent monocytes at steady state [60,
61]. Langerhans cells are DCs within the epidermis and
other squamous epithelia, which rely on M-CSF for their
development [60, 62]. In histiocytosis X, the expansion of
Langerhans cells ismanifested by either granuloma formation
or a more diffuse proliferative disease [63].
Another classification subdivides DCs into resident and
migratory DCs [23]. Resident DCs traffic directly to lym-
phoid tissue from a blood precursor, whereas migratory DCs
first enter tissue before moving to lymph nodes [64–66]. DC
populations express distinct pattern recognition receptors
[67] and play different roles in nature. Monocyte-derived
DCs can be observed in lymphoid tissue in response to infec-
tion with Leishmania major [68] or Listeria monocytogenes
[69].
The development of DCs with either immunogenic or
regulatory activity depends on a series of biological pro-
cesses including differentiation, expansion, migration, anti-
gen uptake and processing, and maturation.
3. DC Maturation
Under homeostatic conditions, tissue-resident DCs are
immature and express low levels of major histocompatibility
complex (MHC) class II and little or no T-cell costimulatory
molecules.The role of immature DCs is not precisely defined,
as they can give rise to either mature DCs or semimature reg-
ulatory DCs that share some phenotypic traits of mature DCs
(e.g., CCR7 chemokine receptor expression [70]). Immature
DCs sense the presence of pathogen- and damage-associated
molecular patterns (PAMPs and DAMPs) from microbial
agents and damaged cells, respectively, and activate proin-
flammatory molecular signaling cascades, such as nuclear
factor kappa B (NF𝜅B) and interferon responsive factor (IRF)
pathways [71, 72]. Activation of these signaling pathways is
associatedwithDCmaturation.MaturingDCs lose their abil-
ity to take up soluble antigen and acquire T-cell stimulatory
activity as a result of increased antigen processing capacity
and upregulation of MHC, T-cell costimulatory molecules,
and proinflammatory cytokines [73, 74]. Traffic molecules
(e.g., CCR7) are upregulated in maturing DCs, allowing
them to migrate to lymphoid tissue [70, 75–78]. In vitro,
mature DCs present “probing movements” characterized by
the incessant lengthening and retraction of long processes
from the cell body [79]. Steady-state DCs in intact lymph
nodes in vivo extend and retract processes in a fairly similar
way [80]. Immature DCs and, to a lesser extent, mature
DCs take up particles and apoptotic cells [81, 82]. Uptake
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Table 1: Recent advances in DC biology, tolerogenic DCs, and pharmacological conditioning protocols.
Authors Reference
Tolerogenic DCs
Constitutive ablation of DCs breaks self-tolerance of CD4+ T cells leading to fatal
autoimmunity Ohnmacht et al. [19]
Tolerogenic DCs favor graft tolerance through interferon-𝛾 and Epstein-Barr virus-induced
gene 3 Hill et al. [20]
Tolerogenic DCs generated with immunosuppressive cytokines induce antigen-specific anergy
and regulatory properties in memory CD4+ T cells Torres-Aguilar et al. [21]
DC genealogy
DC and monocyte lineages originate from a common progenitor that gives rise to monocytes
and committed DC progenitors, which give rise to lymphoid tissue DCs and nonlymphoid
tissue DCs
Liu and Nussenzweig [22]
DCs in mouse lymphoid organs in the steady state are monocyte independent and require Flt3L
for their development. Other tissue may contain additional M-CSF-dependent monocytes
Steinman and
Idoyaga [23]
The differing origins of gut DCs may explain how the intestinal immune system manages to
destroy harmful pathogens while tolerating beneficial bacteria Laffont and Powrie [24]
Comparative genomics reveals functional equivalences between human and mouse DC subsets Crozat et al. [25]
Plasmacytoid DCs (pDCs)
Compared to conventional DCs, pDCs show reduced costimulatory molecule expression and
poor T-cell allostimulatory capacity. Under homeostatic conditions, nonlymphoid
tissue-resident pDCs regulate mucosal immunity and the development of both central and
peripheral tolerance
Rogers et al. [26]
Human pDCs preferentially express immunoglobulin-like transcript 7 (ILT7), which activates
an immunoreceptor tyrosine-based activation motif- (ITAM-) mediated signaling pathway Cao and Bover [27]
Pharmacological DC conditioning
Rapamycin-conditioned, alloantigen-pulsed DCs present donor MHC class I-peptide via the
semidirect pathway and inhibit survival of antigen-specific CD8(+) T cells
Thomson et al. and
Fischer et al. [28, 29]
Human rapamycin-treated DCs are only partially maturation resistant in vivo Macedo et al. [30]
Adenosine A2AR agonist-conditioned DCs attenuate acute renal ischemia-reperfusion injury Li et al. [31]
Vitamin D3-conditioned DCs induce effector T-cell apoptosis and antigen-specific Tregs Nikolic and Roep [32]
Role of conventional DCs of the recipient in tolerogenic DC therapy
Depleting recipient DCs at the time of tolerogenic DC therapy abrogates its beneficial effect Divito et al.,Wang et al. [33, 34]
Role of exosomes
Exosomes mediate transfer of functional microRNAs between mouse DCs Montecalvo et al. [35]
Exosomes from immature DCs plus rapamycin induce tolerance to mouse cardiac allografts Li et al. [36]
Clinical studies of tolerogenic DCs
Phase-1 trial of autologous tolerogenic DC therapy in patients with type-1 diabetes Giannoukakis et al. [37]
Clinical trials of tolerogenic DC therapy in patients with rheumatoid arthritis Hilkens and Isaacs [38]
OneStudy phase-1 trial of autologous tolerogenic DC therapy after kidney transplantation Moreau et al. [39]
of apoptotic cells has been implicated in antigen cross-
presentation, a mechanism that entails either immune tol-
erance under homeostatic conditions or immune activation
uponDCmaturation [83]. In addition,DCs participate in two
“nonclassical” pathways of antigen presentation that involve
autophagy of cytosolic components for presentation onMHC
class II and cross-presentation of endocytosed substrates on
MHC class I [84]. Peptide-MHC-class II complexes formed
in lysosomes during DC maturation move to the cell surface
[85–87] and interact with the T-cell receptor. Maturing DCs
upregulate T-cell costimulatory molecules including CD80,
CD86, CD40, OX40L, and inducible T-cell costimulator
ligand (ICOSL/CD275) [88, 89], along with proinflammatory
cytokines (e.g., IL-1𝛽, IL-2, IL-6, IL-8, IL-12, and IL-18).
The costimulation paradigm dictates that strong T-
cell activation requires three distinct signals: the antigenic
stimulus provided by MHC presenting a cognate peptide,
costimulatory molecules, and stimulatory cytokines. Antigen
presentation in the absence of strong costimulation can
induce a state of antigen-specific T-cell unresponsiveness
or anergy. Repetitive stimulation with allogeneic immature
humanDCs has been shown to induce IL-10-producing, non-
proliferating CD4+ T cells with regulatory activity [90]. Sys-
temic injection of immature, but not of mature, donor bone
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Figure 1: Regulatory T cells (Tregs) are present in the host at the time of transplantation and are recruited to the allograft. They respond to
donor alloantigen through cross-reactivity and inhibit T-cell proliferation in draining lymphoid tissue. Tolerogenic DCs favor the generation
of Tregs from naive T cells, which then block effector T-cell proliferation while also triggering apoptosis of these cells. They inhibit TH1
cells.These processes facilitate allograft acceptance through several mechanisms including the production and release of immunosuppressive
cytokines, such as IL-10 and TGF𝛽 (modified fromWood et al. [2]).
marrow-derived CD8𝛼− DCs to the recipient before engraft-
ment prolonged cardiac allograft survival in the absence
of immunosuppression in mice [91, 92]. Both immature
and comparatively mature CD8𝛼+ “lymphoid-related” DCs
injected 7 days before transplantation likewise prolonged
cardiac allograft survival in fully MHC-mismatched mice
[93]. Moreover, systemically injected donor DCs prevented
rejection of MHC-mismatched skin grafts [94] and lethal
acute graft-versus-host disease [95] in mice. Immature DCs
derived from recipient bone marrow progenitors similarly
improved cardiac allograft survival in mice [96].
Immature DCs with inhibitory properties can be gener-
ated from monocyte precursors in vitro [97]. Alternatively,
immature DC precursors can be mobilized in the live
donor by Flt3L or granulocyte-colony stimulating factor (G-
CSF), collected by leukapheresis, purified, and injected to
the recipient before transplantation. However, this is not
a feasible method with deceased donors, such as in heart
transplantation. In human, bonemarrow cell mobilization by
G-CSF preferentially increased circulating plasmacytoid DC
precursors [98].
4. DCs and Tregs
DCs continuously present harmless self- and nonself-
antigens in a way that favors tolerance. Following antigen
presentation in the absence of costimulatory signals in mice,
immature DCs induce conventional naive T cells to convert
intoTregs and boost the regulatory activity of existingTregs at
once [99–106]. Immature DCs in secondary lymphoid tissue
accumulate antigen and bolster the generation of Tregs that
promote antigen-specific tolerance. Mice lacking functional
immature DCs develop fatal autoimmune disease, possibly
owing to low numbers of Tregs [19, 61, 107, 108]. Mammals,
including human, lacking functional Tregs likewise develop
fatal autoimmune disease [109].
Regulatory DCs interact with Tregs in bidirectional ways.
Tregs express inhibitory receptors, such as cytotoxic T-
lymphocyte antigen 4 (CTLA4), lymphocyte-activation gene
3 (LAG-3), and glucocorticoid-induced tumor necrosis factor
receptor (GITR), along with anti-inflammatory cytokines
such as TGF-𝛽, IL-10, and IL-35 [110, 111]. TGF-𝛽 is a
central mediator in the generation of Tregs [112, 113]. These
cells can be subdivided into CD4+ natural Tregs that are
formed during thymic development in the fetus [114–116] and
adaptive Tregs. The transcription factor Foxp3 is upregulated
in developing T cells upon recognition of self-antigen in
the thymus and controls the function of Tregs [114, 117].
Natural Tregs can convert into adaptive CD4+ or CD8+ Tregs
in secondary lymphoid organs. In two human volunteers,
a single subcutaneous injection with autologous immature
monocyte-derived DCs pulsed with influenza matrix peptide
induced IL-10-producing, peptide-specific CD8+ Tregs and
suppressed peptide-specific killing activities of CD8+ T cells
[118]. These results indicate that immature DCs can induce
Tregs and inhibit antigen-specific effector T cells in human.
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5. Tolerogenic DCs
Immature DCs are comprised of distinct populations that
differ in their capacity to present antigen, produce cytokines,
and promote tolerance. Phenotypically mature DCs are not
always immunogenic. For instance, immature DCs that
upregulate MHC and costimulatory molecules after in vitro
treatment with TNF-𝛼 or IFN-𝛾, a typical attribute of mature
DCs, but are still able to promote the generation of Tregs
from naive T cells, have been described [119, 120]. Also,
some immature DCs in peripheral tissue express high levels
of CCR7, another typical feature of mature DCs, while
maintaining the capacity of inducing Tregs [121–124]. CCR7
deficiency prevents lymphatic migration of immature DCs
and induction of inhaled and oral tolerance, indicating a
major role for this chemokine receptor in tolerance induction
[125].
PlasmacytoidDCs, originally identified as a subset ofDCs
that produce type I interferons in response to viral infec-
tion, differ from traditional DCs in several ways including
decreased costimulatory molecule expression and reduced
allostimulatory capacity. Human plasmacytoid DCs prefer-
entially express immunoglobulin-like transcript 7 (ILT7) that
couples with a signaling adapter to activate a prominent
immunoreceptor tyrosine-based activation motif- (ITAM-
) mediated signaling pathway [27]. Nonlymphoid, tissue-
resident plasmacytoid DCs are key cellular players in the
regulation of mucosal immunity at steady state and in the
induction of central and peripheral tolerance. They have
been associated with generation of alloantigen-specific CD4+
Tregs or CD8+ Tregs that promote graft tolerance [26,
54, 57, 126–133] and long-term cardiac allograft survival
[131, 132].
Natural tolerogenic DCs originate from hematopoi-
etic precursors and maintain tolerance constitutively under
homeostatic conditions [134]. In the thymus, where central
tolerance is set up, natural tolerogenic DCs induce the gener-
ation of Foxp3+ natural Tregs by a mechanism that is medi-
ated by IL-7-related thymic stromal lymphopoietin (TSLP)
produced by Hassall’s corpuscles in the thymic medulla [135].
Induced tolerogenicDCs differ fromnatural DCs in that their
tolerogenic activity is controlled by molecular signals from
the environment, such as TGF-𝛽 and IL-10 in the intestinal
mucosa, which oppose maturation stimuli. In vitro treatment
of immature DCs with these anti-inflammatory cytokines
promotes the development of tolerogenic DCs that assist in
the conversion of naive T cells into Tregs more effectively
than the immature DCs themselves. Several strategies have
been developed to generate tolerogenic DCs for therapeutic
use in organ transplantation [44, 136–142]. The two major
general approaches consist of pharmacological conditioning
and genetic engineering of immature DCs.
5.1. Pharmacologically Conditioned DCs. Thedevelopment of
immunosuppressive drugs has traditionally been focused on
inhibition of lymphocyte proliferation, which was initially
perceived as a key process in immune responses to all kinds of
antigens. By screening many agents for inhibition of lympho-
cyte proliferation, Schwartz and Dameshek discovered the
immunosuppressant 6-mercaptopurine in 1959 [143]. Over
the past two decades, it has been increasingly recognized
that many drugs that primarily act by inhibiting T-cell
proliferation concurrently modulate DC function.
Glucocorticoids inhibit DC differentiation and matura-
tion both in vitro and in vivo [144–150]. Dexamethasone pref-
erentially blocked the differentiation of plasmacytoid DCs
and enhanced their apoptotic death [150]. DCs conditioned
by vitamin D
3
in vitro exhibited several attributes of tolero-
genicDC, such as resistance tomaturation, IL-10 release upon




played a semimature phenotype, anti-inflammatory proper-
ties, and lowT-cell allostimulatory capacity [153]. T cells from
patients with relapsing remitting multiple sclerosis cultured
with autologous vitamin D
3
-treated DCs loaded with myelin
peptides induced hyporesponsiveness of myelin-reactive T
cells [153]. Synergistic effects of vitamin D
3
and dexametha-
sone have been reported [149]. Vitamin D
3
combined with
dexamethasone was used to derive tolerogenic DCs from
healthy subjects and from patients with rheumatoid arthritis
[154]. In vitro LPS-stimulated tolerogenic DCs, referred to
as “alternatively activated” DCs, exhibited enhanced ability
to migrate to lymphoid tissue and to present antigen. They
induced memory T-cell hyporesponsiveness, proliferation of
naive T cells, low IFN-𝛾 expression, and high IL-10 expression
[155, 156].
DCs conditioned by IL-10 or other immunosuppressive
cytokines in vitro promoted antigen-specific anergy and
regulatory activity in memory CD4+ T cells [21, 157]. Two
different populations of DCs were derived from monocytes
cultured in the presence of GM-CSF and IL-4, depending
on the time point of their exposure to IL-10. When IL-10
was added at the end of culture, DCs showed an immature
phenotype, were resistant to maturation [158, 159], and
induced antigen-specific CD4+ and CD8+ T-cell anergy
[159–161]. DCs derived from macaque monocytes treated
with vitamin D
3
and IL-10 were resistant to maturation
and displayed low T-cell allostimulatory activity in vitro
[162]. Systemic injection of these DCs to MHC-mismatched
recipient macaques treated with antihistamine drug and
CTLA4Ig (soluble CTLA4-immunoglobulin fusion protein)
elicited a transient increase in donor antigen-specific T-
cell proliferation, with no changes in antidonor antibodies
[162]. Conversely, when IL-10 was added at the initiation of
monocyte culture, the differentiating DCs expressed CD83,
CD80, and CD86, similar to mature cells, but also Ig-like
transcript- (ILT-) 2, ILT3, ILT4, and human leukocyte antigen
G, similar to tolerogenic DCs [163]. Importantly, IL-10-
treated DCs supported the differentiation of type-1 Tregs
(Tr1) [163, 164]. On the other hand, IL-10 downregulated
CCR7, thereby impairing lymphoid homing of DCs in vivo
[165, 166].
CyclosporineA and tacrolimus (FK-506), two calcineurin
inhibitors, inhibited IFN-𝛾 production and MHC-restricted
antigen presentation by myeloid DCs [167], as well as acti-
vatory interactions of DCs with T cells [168]. In one study
[169], cyclosporine A downregulated chemokine receptors
and cyclooxygenase-2 (COX-2). This effect was associated
6 Journal of Transplantation
with impaired DC migration. However, another study [166]
showed that cyclosporine A and tacrolimus, unlike dex-
amethasone and IL-10, did not downregulate CCR7 nor
did they inhibit CCL19 chemokine-mediated migration of
human monocyte-derived DCs in vitro or lymphoid homing
of mouse DCs in vivo.
Another importantmolecule used to generate tolerogenic
DCs is mycophenolate mofetil. This agent inhibits T- and
B-cell proliferation by interfering with de novo synthesis
of purines required for the production of nucleic acids.
Mycophenolate mofetil inhibits the maturation of DCs in
vitro and their immunostimulatory capacity in vivo [170].
Aspirin [171–174] and deoxyspergualin [175], two
inhibitors of the NF-𝜅B signaling pathway, likewise inhibit
DCmaturation. Immature host DCs conditioned ex vivowith
oligodeoxynucleotides (ODN) against NF-𝜅B achieved long-
term cardiac allograft survival in rats [176]. Blocking NF-𝜅B
signaling during human DC differentiation induced anergy
and Treg activity for one, but not two, HLA-DR mismatches
[177]. Interestingly, a clinical study showed a significant
correlation between low-dose aspirin therapy and improved
allograft function and survival in kidney transplant recipients
[178]. Systemic administration of immature autologous
myeloid DCs combined with a deoxyspergualin derivative
induced donor-specific tolerance in a heart transplant
model in rats [20]. This effect was associated with an
increase in NK−TCR𝛼𝛽+CD3+CD4−CD8−double negative
Tregs, a population that has been linked to donor-specific
improvement of graft survival [179], but not in conventional
CD4+CD25+Foxp3+ or CD8CD45RClow Tregs in host
spleens. The double negative Treg population expressed
IFN-𝛾. This cytokine is produced by alloantigen-reactive
CD4+Foxp3+ Tregs and enhances their regulatory activity
in vivo through an autocrine mechanism [180]. IFN-𝛾
also induces the development of Foxp3+ Tregs from CD4+
CD25−cells. These findings indicate that IFN-𝛾 released by
double negative Tregs potentiates their ability to suppress
alloreactive CD4+ and CD8+ T cells [181].
Rapamycin, an immunosuppressive macrolide, inhibits
the integrative kinase mammalian target of rapamycin
(mTOR). Inhibition of mTOR exerts immunoregulatory
activity [182] including attenuated innate immune responses
[183]. Mouse monocyte-derived DCs conditioned by rapa-
mycin in vitro were resistant to maturation induced by
inflammatory stimuli while conserving their ability to
migrate to lymphoid tissue and to enrich the naturally
occurring CD4+ Tregs. Intravenous injection of host rapa-
mycin-treated DCs pulsed with donor antigen before
heart transplantation, combined with a short course of
immunosuppression, prolonged allograft survival indefi-
nitely in rodents [28–30, 184, 185]. Rapamycin-treated
DCs expressed CD83, CD86, low levels of IL-10, and high
levels of IL-12p40/p70 [186]. Although these features were
typical of a mature phenotype, these DCs inhibited T-cell
alloproliferation, similar to those treated with vitamin D3
and dexamethasone [187]. Upon LPS stimulation, they
expressed high levels of IL-12 [28], a cytokine that parti-
cipates in the generation of Foxp3+ Tregs. However, human
rapamycin-treated DCs, unlike murine, were only partially
maturation resistant in vivo [30].
DC-mediated NK T-cell activation is a critical event in
the early immune response to renal ischemia/reperfusion
injury. DCs treated with adenosine 2A receptor (A
2
AR)
agonists protected the kidney from ischemia/reperfusion
injury through suppression of IFN-𝛾 production by NK T-
cells and decreased costimulatory molecule expression [31].
In a recent study [188], protein kinase C inhibitors induced
the development of stable human tolerogenic DCs.
5.2. DCs Generated in the Presence of Low-Dose GM-CSF
without IL-4. A combination of high-dose GM-CSF and
IL-4 has been used as a standard protocol for generation of
DCs from bone marrow precursors in vitro. Although DCs
generated using this protocol induced primary allogeneic
T-cell anergy in vitro, they were not resistant to matura-
tion. The potential of tolerogenic DCs to mature within an
inflammatory environment, turning into immunogenic cells
in vivo, is of major concern to therapeutic applications [47].
An alternative protocol consists of culturing bone marrow
precursors with low-dose GM-CSF in the absence of IL-4.
Mouse DCs generated using this protocol efficiently captured
and presented antigen, were maturation-resistant and poor
stimulators of T-cell proliferation, and prolonged cardiac
allograft survival in vivo [92]. DCs derived from monkey
bone marrow in the presence of GM-CSF without IL-4
gave rise to two populations showing a similar phenotype
but different functional properties. The adherent population
displayed immunoregulatory properties that were correlated
with upregulation of heme oxygenase-1 (HO-1), an anti-
inflammatory enzyme, both in vitro and in a rat allotransplant
model in vivo. Conversely, the nonadherent population was
immunogenic [189]. Immature DCs derived from human
bone marrow by low doses of GM-CSF in the absence of IL-4
were resistant to common maturation stimuli and exhibited
tolerogenic properties in vitro [47, 190], including induction
of T-cell anergy in naive allogeneic T cells when stimulated
twice with immature DCs [47]. Therefore, the establishment
of the anergic state appeared to require two subsequent
stimulations by immature DCs.
5.3. Tolerogenic DC Therapy Combined with Immunosup-
pressive Drug Administration. In vivo injection of imma-
ture DCs can be combined with the systemic adminis-
tration of immunosuppressive drugs. For instance, imma-
ture donor DC therapy combined with either anti-CD154
(CD40 ligand) antibody [191] or anti-CD54 (intercellular
adhesion molecule) antibody together with CTLA4Ig [192]
prolonged cardiac allograft survival in mice for more than
100 days. Likewise, adoptive transfer of immature donor
DCs combined with anti-CD154 antibody inhibited intimal
hyperplasia and arterial lesions in mouse aortic allografts
[193]. Alloantigen-pulsed, rapamycin-treated DCs combined
with a low dose of rapamycin administered at the time of
transplantation induced indefinite cardiac allograft survival
in mice [184]. Moreover, mature donor DCs combined with
a systemic treatment with tacrolimus prolonged cardiac
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allograft survival in rats, whereas DCs alone were ineffective
in this model [194]. Other studies did not support synergistic
effects of tolerogenic DC therapy and systemic treatment
with rapamycin or cyclosporine A in transplant models
[167]. On the other hand, immunosuppressive drugs can
modify DC function and hinder the efficacy of tolerogenic
DC therapy. As an example, tacrolimus inhibits the ability
of DCs to process and/or present antigen [167, 195]. For
these reasons, interactions of systemic drug treatments with
injected tolerogenic DCs need to be investigated in animal
models before the initiation of clinical trials, as discussed
below.
5.4. Genetically Modified DCs. One critical aspect of tolero-
genic DC therapy is the stability of tolerogenic DCs, which
should not turn into immunogenicDCs in vivowhen exposed
to proinflammatory cytokines. This consideration is impor-
tant in transplantation, a condition associated with chronic
inflammation. Semimature tolerogenicDCs have been shown
to convert into immunogenic DCs in an inflammatory
environment in vivo [196, 197], which can accelerate graft
rejection. Because the conditioning effect by pharmacolog-
ical agents on DCs in vitro may not last in vivo, genetic
engineering of DCs to express an immunosuppressive factor
may represent an attractive approach. Genetically modified
DCs can express the therapeutic gene for extended periods
of time in vivo. Because DCs are manipulated genetically
in vitro, the recipient is not directly exposed to the gene
transfer vector. Recombinant adenovirus vectors have been
used inmany studies due to their high efficiency, despite their
proinflammatory effects that entail DC maturation [198].
Recombinant retrovirus vectors and nonviral gene transfer
systems may induce lower levels of DC maturation [199].
With respect to the transgene which is to be constitutively
expressed by DCs, candidates include genes that encode
an immunosuppressive cytokine, a costimulatory inhibitor,
a death ligand that causes killing of effector T cells, a
chemokine receptor, or an adhesion molecule that mediates
lymphoid homing, among others.
Early studies focused on DCs constitutively expressing
immunosuppressive cytokines, particularly IL-10, IL-4, and
TGF-𝛽 [200–208]. These approaches had limited effects
on allograft survival. We have shown that bone marrow-
derived mouse DCs constitutively expressing indoleamine
2,3-dioxygenase (IDO), an inhibitor of T-cell activation,
attenuated T-cell alloproliferative responses in the mixed
leukocyte reaction in vitro [209]. DCs expressing soluble
CTLA4Ig significantly prolonged both cardiac and islet allo-
graft survival in rodents [210–214]. However, this approach
was not significantly more effective than CTLA4Ig peptide
treatment or direct CTLA4Ig gene delivery into the graft.
By binding the cell death receptor Fas (CD95), Fas ligand
participates in the maintenance of peripheral T-cell tolerance
andmaintenance of immune privilege in certain organs. DCs
expressing transgenic Fas ligand inhibited antigen-specific T-
cell responsiveness, prolonging the survival of fully MHC-
mismatched cardiac allografts in some studies [215, 216], but
not in others [217, 218]. Mouse tolerogenic DCs generated
with antisense ODN against the costimulatory molecules
CD40, CD80, and CD86 remained costimulatory deficient
in vivo, even after 3 weeks of injection [219]. Low CD40
expression translates into low levels of cytokine (IL-12, TNF-
𝛼) production upon CD40 ligation [219]. DCs generated with
antisense ODN against CD80/86 prolonged allograft survival
in a transplant model [220]. Similar findings were reported
with immature DCs constitutively expressing soluble TNF-𝛼
type-1 receptor (sTNFR-1) [221]. DCs engineered genetically
to express CCR7 showed enhanced lymphoid homing. Injec-
tion of DCs constitutively expressing both IL-10 and CCR7,
but not those expressing either gene alone, prolonged cardiac
allograft survival in mice [222]. This finding exemplifies
synergistic effects resulting from simultaneous targeting of
multiple parameters of DC function, such as maturation and
lymphoid homing.
Galectin- (gal-) 1 is an endogenous inhibitor of T-cell
activation, DC function, and immune cell trafficking [223–
225]. DCs deliver tolerogenic signals to T cells through a gal-
1-driven immunoregulatory circuit that involves IL-27 and
IL-10 [226]. Lung cancer-derived gal-1 mediates DC anergy
through inhibitor of DNA binding 3/IL-10 signaling pathway
[227]. Gal-1 and -3 genes silencing in immature and mature
DCs enhance T-cell activation and IFN-𝛾 production [228].
DCs constitutively expressing gal-1 delayed onset of autoim-
mune diabetes in mice [223]. Moreover, gal-1 prolonged
liver allograft survival from Flt3L-pretreated donors in mice
[229]. Mice deficient in gal-1 showed accelerated CD8+ T-
cell-mediated rejection of skin allografts [230].These findings
establish gal-1 as an attractive candidate for gene therapy for
transplantation.
5.5. DCs Conditioned by Donor Apoptotic Cells and Exo-
somes. An emerging strategy consists of in situ delivery of
donor antigen to quiescent host DCs using donor apoptotic
cells or exosomes [231, 232]. The latter are 40–100 nm size
membrane vesicles rich in microRNA, which play important
roles in intercellular communication [233], including the
transfer of functional microRNA molecules between DCs
[35]. Interaction or phagocytosis of cells in early apoptosis
exerts a potent anti-inflammatory and immunosuppressive
stimulus on DCs and macrophages. In situ-targeting of DCs
with donor apoptotic cells restrained indirect allorecognition
and attenuated graft vasculopathy in a transplant model
[234]. Systemically delivered exosomes rich in donor MHC
molecules were taken up by host DCs and prolonged allograft
survival [231]. Exosomes from immature DCs combinedwith
rapamycin induced tolerance to cardiac allografts in mice
[36].
5.6. Tolerogenic DC Therapy May Act through Conven-
tional DCs of the Host. Recent evidence suggests that in
vivo injected immunosuppressive DCs may attenuate allore-
sponses and improve cardiac allograft survival, not by
themselves, but through quiescent conventional DCs of the
recipient [33, 34]. Indeed, transient depletion of conventional
DCs of the recipient by the time of DC therapy abolished
its beneficial effect on graft survival. This phenomenon was
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also observedwhen immunosuppressiveDCswere combined
with low-dose pharmacological immunosuppression. Fol-
lowing DC therapy, presentation of donor-derived peptides
by conventional DCs led to preferential deletion of indirect-
pathway CD4+ effector T cells, increasing the percentage of
Foxp3+ CD4+ T cells [33]. These results are in line with
earlier studies showing that i.v. injection of donor immuno-
suppressive DCs before heart transplantation inhibited anti-
donor responses through the direct pathway, which involves
recognition of intact donor MHC molecules by recipient
T cells [92, 210]. The high precursor frequency of direct-
pathway T cells and their predominance in most in vitro
assays of alloreactivity led to the assumption that the direct
pathway was the dominant mechanism of allorecognition
during acute cardiac allograft rejection and that systemic
injection of donor immunosuppressive DCs inhibited direct
responses by interacting with direct-pathway T cells [34].
The aforementioned findings regarding transient depletion
of recipient DCs at the time of donor DC therapy [33]
demonstrate that depletion of conventional DCs prevents
not only downregulation of the indirect T-cell pathway, as
anticipated, but also the direct-pathway response elicited by
cardiac allografts. This observation suggests that, in vivo,
donor-derived immunosuppressive DCs by themselves are
unable to downregulate direct T-cell responses in the absence
of conventional DCs of the recipient [34].
Because generation of donor immunosuppressive DCs is
not applicable to deceased donors, use of host DCs pulsed
with donor antigen has been viewed as a more feasible
method in clinical heart transplantation.Within this context,
pulsing host DCs with donor antigen has been used to inhibit
the indirect pathway of allorecognition [235, 236]. However,
the aforementioned study [33] indicated that systemically
injected host immunosuppressive DCs pulsed with MHC
class I- or MHC class II-restricted peptides mediated their
beneficial effect through conventional DCs of the recipient.
These findings suggest that the intrinsic immune regulatory
activity of delivered DCs in vivo may be less important than
what was previously thought. They also raise the question as
towhether the function of conventionalDCs of the recipients,
which are required for the efficacy of DC therapies, is
preserved in transplant candidates with an end-stage disease.
5.7. Clinical Applications of Tolerogenic DCs. While several
clinical trials of immunogenic DC therapy for cancer have
been performed [237, 238], clinical DC-based “negative vac-
cination” is still verymuch in its infancy. In 2001, a pioneering
study showed that autologous immature DCs injected sub-
cutaneously into healthy volunteers were well tolerated, did
not cause autoimmunity, and induced antigen-specific CD8+
Tregs along with antigen-specific T-cell hyporesponsiveness
[118, 239]. Recently, proof of safety for tolerogenicDC therapy
was provided by a clinical phase-1 trial in 10 patients with
type-1 diabetes who received an intradermal injection of
autologous DCs generated in the presence of GM-CSF and
IL-4, with or without antisense ODN against CD40, CD80,
and C86 [37]. No adverse effects were observed. Meanwhile,
two clinical trials of tolerogenic DC therapy in patients
with rheumatoid arthritis have been started [38, 240]. Other
trials are in progress or are imminent. In transplantation,
the OneStudy phase-1 clinical trial has been designed to
evaluate tolerogenicDC therapy in renal transplant recipients
[39, 241]. Autologous monocyte-derived tolerogenic DCs
will be generated from patients with chronic renal failure.
Each disease condition for which DC therapy is envisaged
can potentially modify the function and in vivo survival
of tolerogenic DCs derived from the recipient. It therefore
is important to test DCs from patients in animal models
before starting a clinical trial. Ahead of the clinical trial in
kidney transplantation, tolerogenic DCs from patients with
chronic renal failure have been validated in a skin transplant
model [241]. Moreover, tolerogenic DCs from patients with
rheumatoid arthritis were compared with those from healthy
controls before the initiation of a clinical trial for this disease;
tolerogenic DCs from the two groups showed a similar
phenotype and in vitro function [154]. Ahead of a clinical
trial in patients with relapsing-remitting multiple sclerosis,
tolerogenic DCs generated with vitamin D
3
from these
patients were compared with those derived from healthy
controls and found to have a comparable phenotype and
function [153].
In renal transplant recipients enrolled in the OneStudy
trial and treated with tolerogenic DC therapy, drug-based
immunosuppression consisting of low doses of mycopheno-
latemofetil, tacrolimus, and prednisolone is not discontinued
[241]. This raises the question as to whether these drugs
could modify the function of injected tolerogenic DCs in
vivo. As already mentioned, immunosuppressive drugs can
either enhance or hamper the effect of DC therapy. In
preliminary experiments performed ahead of the OneStudy
trial, tolerogenic DC therapy did not impair, but actually
slightly enhanced, the effect of mycophenolate mofetil on
graft survival in a transplant model [241]. While tacrolimus
inhibits the ability of DCs to process and/or present antigen
[167, 195], tacrolimus immunosuppression has been shown
to prolong cardiac allograft survival after in vivo injection of
mature donor DCs in a transplant model [194]. Before the
initiation of a clinical trial, it is therefore important to assess
graft survival with each immunosuppressive drug to be used
in the trial, with and without DC therapy, in a transplant
model.
Another aspect that affects immunogenicity and sur-
vival of injected DCs in vivo is the route of administra-
tion. In one study [242], dexamethasone/LPS-treated DCs
prolonged mouse cardiac allograft survival when delivered
intravenously, whereas they were ineffective when delivered
subcutaneously. Recent evidence in monkeys suggests that
autologous tolerogenic DCs may prime an immune response
when delivered intradermally, but not when delivered intra-
venously [39]. In another study in monkeys, intravenous
injection of tolerogenic DCs was well tolerated [162].
An unresolved issue in DC therapy for transplantation is
the choice between donor and recipient DCs. Most studies
have utilized donor DCs or recipient DCs loaded with donor
peptides. The OneStudy trial in kidney transplantation has
been designed to evaluate autologous DCs not pulsed with
donor antigens [39]. The investigators pointed out that a risk
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of donor sensitization due to the presence of a slight contam-
inant cell product or the destruction of the injected cells by
nonself-recognition [243] could not be excluded using tolero-
genic DCs from the donor [39], whereas such a risk should
be minimized using autologous DCs. In addition, donor
DCs or recipient DCs pulsed with donor peptides require
LPS or cytokine stimulation for efficient lymphoid homing
and antigen presentation in transplant models (“alternatively
activated” DCs) [155, 156]; however, such a stimulation can
foster DCmaturation. On the contrary, autologous immature
DCs donot need LPS stimulation in rodent transplantmodels
[96]. Also, recent evidence suggests donor DCs may die
quickly after in vivo injection, and the effect of DC therapy
may be mediated by endogenous DCs [33, 34], as discussed
above. To the opposite, autologous immature DCs have been
detected in the spleen of recipient rats at least two weeks
after in vivo injection [96]. Thus, autologous DCs may offer
several advantages over donorDCs as a source for tolerogenic
DCs [39]; however, this question has not been answered
definitively.
6. Concluding Remarks
Studies in rodent and monkey transplant models have pro-
vided proof of principle for tolerogenic DC therapy for solid-
organ transplantation. Clinical trials testing this strategy
have been carried out in patients with type-1 diabetes or
rheumatoid arthritis, and a trial in renal transplant recipients
has been designed. Nevertheless, several important ques-
tions remain. Are autologous DCs superior to donor DCs?
Should autologous DCs be pulsed with donor antigen? Are
genetically engineered DCs superior to pharmacologically
conditioned DCs? Does maintenance drug-based immuno-
suppression influence the outcome of DC therapy? Which
immunosuppressive drugs are most suitable in this regard?
What is the best time for DC administration? How can DCs
be made truly maturation resistant in vivo? As conventional
DCs of the recipient seem to be critical for the success of
tolerogenic DC therapy, would it be possible to promote tol-
erance without any cell injection? Answering these questions
will likely advance the field and optimize these approaches.
Meanwhile, a successful completion of the first clinical trial
of DC therapy in transplantation may open a new avenue in
the field.
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